How Long Does Apixaban
Stay in Your System?

Apixaban — sold under the brand name Eliquis — is one of the most widely prescribed anticoagulants (blood thinners) in the world. It is a direct Factor Xa inhibitor used to prevent stroke and blood clots in people with atrial fibrillation, and to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE). It is taken twice daily in most indications.

How Long Does Apixaban Stay in Your System?

Apixaban has an elimination half-life of approximately 12 hours. After a single dose, it takes roughly 2–3 days (5 half-lives, approximately 60 hours) to be fully cleared from your system. With twice-daily dosing, apixaban reaches a steady state within 3 days, and takes 2–3 days to clear after the last dose is stopped.

Apixaban is eliminated via multiple pathways: approximately 27% is excreted unchanged in the urine, and the remainder is metabolised in the liver (primarily via CYP3A4) and excreted via faeces. This dual elimination pathway makes apixaban less sensitive to kidney impairment than some other anticoagulants like dabigatran.

How Long Before Surgery Should I Stop Apixaban?

This is one of the most common questions about apixaban. Current guidelines recommend:

• Low-to-moderate bleeding risk procedures (e.g. dental extractions, minor skin procedures, endoscopy without biopsy): stop apixaban 24 hours before the procedure.
• High bleeding risk procedures (e.g. major orthopaedic surgery, neurosurgery, cardiac surgery, major abdominal surgery): stop apixaban 48 hours before the procedure.
• Very high bleeding risk or patients with renal impairment: stopping 72 hours in advance may be required.

Always follow your surgeon's or cardiologist's specific instructions. The decision to stop anticoagulation must balance bleeding risk against the risk of stroke or clot formation — never stop apixaban without explicit medical guidance.

What Affects How Long Apixaban Stays in Your System?

• Kidney function — Reduced kidney function slows apixaban clearance. In severe renal impairment, dose reduction is required. In patients with very severe renal impairment (CrCl < 15 mL/min), apixaban should be used with caution.
• Age — Elderly patients (75+) clear apixaban more slowly, and dose reduction criteria apply (5mg twice-daily is reduced to 2.5mg twice-daily if two of three criteria are met: age ≥80, weight ≤60kg, creatinine ≥1.5 mg/dL).
• Body weight — Very low body weight (≤60kg) increases exposure; very high body weight (>120kg) may reduce exposure slightly.
• CYP3A4/P-gp inhibitors — Strong dual inhibitors such as ketoconazole, itraconazole, and clarithromycin significantly increase apixaban exposure. Dose reduction is recommended in some cases.
• Liver function — Severe hepatic impairment is a contraindication. Moderate impairment increases exposure modestly.

Apixaban is a direct oral Factor Xa inhibitor with an elimination half-life of approximately 12 hours, which supports its standard twice-daily dosing schedule. A practical distinguishing feature compared with other direct oral anticoagulants is its relatively low renal clearance — roughly 27% of an administered dose is recovered in urine — with the remainder eliminated via the faeces and hepatic metabolism. This lower dependence on the kidneys is one reason clinicians often consider apixaban in patients with mild-to-moderate renal impairment. These pharmacokinetic facts are reported in the U.S. FDA prescribing information for Eliquis, the European Medicines Agency public assessment report, and peer-reviewed pharmacology reviews indexed on the NIH's PubMed database.

Sources cross-checked: U.S. FDA prescribing information (DailyMed), U.K. NHS medicines information, and additional official references from the European Medicines Agency, NIH MedlinePlus / LiverTox, the WHO Model List of Essential Medicines, or the American Thyroid Association, depending on the medication. This page is general educational information only and is not medical advice.